US-Based Axiom Seeks Hong Kong IPO

US-based biotech company Axiom is reportedly seeking an Initial Public Offering (IPO) in Hong Kong, aiming to capitalize on China's growing biotechnology market.

21 Jul, 11:00 — 21 Jul, 11:00

Post Share

Sources

Showing 1 of 2 sources

SCMPMostly Factual8d ago

US biotech firm developing therapies for infant brain injuries plans Hong Kong listing

A US-headquartered biotech firm plans to seek a primary listing in Hong Kong, joining a swelling pipeline of artificial intelligence-powered medical players raising capital in the city. Axiom Biosciences, which develops experimental therapies for newborns with severe brain injuries by using AI, is targeting at least US$200 million through an initial public offering (IPO) in Hong Kong in 2027, followed by a secondary listing in the US in 2029. “Some of the most important science in the world i...

By Julie Zhang

Read full article →

Coverage Timeline

First report: bloomberg · 21 Jul, 10:45|Full coverage: 2 · 15m|Window: 15m

Left-leaningCenterRight-leaning

bloomberg21 Jul, 10:45First to report